EFFICACY AND SAFETY OF MARIBAVIR INTHE TREATMENT OF 10 PATIENTS WITH CMV END-ORGAN DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (EHA 2026) - May 13, 2026 - Abstract #EHA-5051; PB4022; "All 10 patients received letermovir (LET) prophylaxis from day +6 to day +100 post-transplantation. Summary/Conclusion Maribavir shows favorable clinical efficacy in the treatment of CMV end-organ disease after allo-HSCT, with mild adverse effects and good tolerability. However, given the small sample size, further validation in large-scale prospective studies is warranted."
Clinical • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Cytomegalovirus Infection • Gastroenterology • Gastrointestinal Disorder • Graft versus Host Disease • Hematological Disorders • Immunology • Infectious Disease • Pneumonia • Respiratory Diseases • Transplantation
|
|
Zhicong Du 1; Fang Xu 2; Yun Wang 2; Baiqing Sun 2; Na Zhang 1; Chunqiong Xu 1; Shanshan Zhang 1; Jianli Wang 1; Juju Xu 1; Yue Lu1
|